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Abstract
The role of Streptococcus species as an aetiological microorganism of vertebral osteomyelitis (VO) is considered to be of little relevance. We
aimed to describe a large number of cases of streptococcal vertebral osteomyelitis (SVO), to analyze the clinical features associated with
different Streptococcus species, and to compare them with a cohort of patients with VO caused by Staphylococcus aureus. An incidence study
and a retrospective, multicenter, observational clinical study of cases of SVO (1991–2011) were performed. Statistical comparison of SVO
by different species and between them and staphylococcal VO was carried out. Over the whole period there was an increasing incidence in
the number of VOs and SVOs per year (p <0.05). Among 58 cases of SVO, those caused by non-viridans streptococcus (Streptococcus
pneumoniae, Streptococcus agalactiae and Streptococcus pyogenes; n = 26) mimicked VO by S. aureus, and presented with more fever,
neurological symptoms and paravertebral abscesses in comparison with those caused by the viridans group (remaining species). In contrast,
the latter have a sub-acute clinical picture and were associated with the presence of endocarditis (p <0.05). Among non-viridans SVOs,
concomitant infection was specifically related to S. pneumoniae (p <0.05). In conclusion, SVO presents a wide range of clinical patterns. The
relationship between VO and diagnosis of endocarditis was established with SVO caused by the viridans group. Whereas non-viridans SVO
mimics acute characteristics of VO caused by S. aureus, cases of viridans SVO are significantly more likely to have a sub-acute clinical
presentation. The increased incidence of SVO during the last decades could support a new epidemiological scenario.
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Introduction
Vertebral osteomyelitis (VO) has increased its incidence in
recent years [1–3]. While Staphylococcus aureus is most
frequently responsible for VO, the role of Streptococcus species
has so far been considered to be of little relevance [2,4].
The classifications developed by Lancefield and by Sher-
man grouped the wide variety of Streptococcus species into
viridans and non-viridans streptococci, depending on their
microbiological characteristics and potential ability to cause
different kinds of infection [5,6]. While there are well-rec-
ognized infections caused by streptococci [7–12], strepto-
coccal vertebral osteomyelitis (SVO) is less widely reported
and, to our knowledge, its particular features have yet to be
described and analysed in detail [2,4,13–15].
Recently, certain epidemiological changes have been pointed
out in relation to VO, including a higher incidence of cases
caused by low-virulence bacteria and those with no microbi-
ological diagnosis [3,16–18]. These cases are characterized by
the slow appearance of signs and symptoms of vertebral
osteomyelitis, mainly in older people with debilitating diseases.
Thus, we hypothesized that low-virulence SVO could be
related to the increased incidence of vertebral osteomyelitis
without microbiological diagnosis.
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The aim of the present study was therefore to analyse
epidemiological changes in SVO over time and to describe the
characteristics of a large number of cases of SVO. We also
sought to analyse the particular clinical features associated
with different Streptococcus species, especially the viridans and
non-viridans groups, and to compare them with a cohort of
patients with VO caused by S. aureus.
Patients and Methods
Setting
This study was performed in the Osteoarticular Infection Units
of three tertiary-care Spanish teaching hospitals (in Barcelona,
Malaga and Seville). The research groups involved have published
several works in the field of vertebral osteomyelitis [3,19–22].
Basic management protocol
Definitions. Vertebral osteomyelitis was diagnosed by the
presence of a compatible clinical picture and characteristic
imaging findings (computed tomography or magnetic reso-
nance imaging) [1,2]. Diagnosis was considered definitive (VO
microbiologically confirmed) if a pyogenic microorganism was
isolated in blood cultures or spinal biopsy specimens, and
probable (vertebral osteomyelitis with no microbiological
diagnosis, VO-NM) if no organism was isolated [1,2]. Con-
comitant infection was defined as any infection (cause or
consequence of the VO) diagnosed at the time of VO.
In line with the Lancefield and Sherman classifications,
Streptococcus species were divided into two groups: non-viri-
dans species (Streptococcus pyogenes, Streptococcus agalactiae
and Streptococcus pneumoniae) and viridans streptococci (Strep-
tococcus bovis and Streptococcus milleri, along with the remaining
species). Endocarditis was diagnosed using Duke criteria [23].
When streptococcal bacteraemia was identified, echocardiog-
raphy was performed if deemed appropriate by clinicians, but it
was not routinely carried out.
Study design
Incidence study. Weregistered all episodes diagnosed or treated
in the three hospitals from 1991 to 2011. Cases from hospitals
were all identified after double checking both the general patient
records of each hospital and the files from the infectious diseases
and rheumatology wards. Incidence data were calculated after
adjusting for the population of our health area per year.
Clinical study. All patients with a diagnosis of VO who were
admitted and prospectively treated in the three hospitals were
included. Cases of facet joint infection with no involvement of
intervertebral disk or vertebral soma, cases caused by
Mycobacterium tuberculosis, Brucella sp. or fungus, and postsur-
gical cases were all excluded. The clinical study period differed
between hospitals: from January 1991 to December 2011 in
Malaga and Seville, and from January 2003 to December 2011
in Barcelona. All cases were retrospectively reviewed and SVO
was identified and analysed. Statistical comparison of cases
coming from different hospitals was performed to ensure that
no differences existed. For further comparisons between SVO
and other VOs, cases of VO caused by S. aureus were
recorded in patients admitted to hospital in Barcelona during
the established study period.
Data collection. Data collected on an itemized form included
the following: (i) underlying medical condition, (ii) vertebral
level involved, (iii) clinical presentation, (iv) microbiological
diagnosis, (v) concomitant infection, (vi) laboratory tests, (vii)
diagnostic imaging data and (viii) treatment procedures.
Follow-up and outcome. Clinical follow-upwas performed by one
of the authors during treatment and up till 12 months thereafter.
Treatment failure was considered if (i) the patient died due
to causes related to the infection, (ii) there was persistence of
infection (isolation of the same microorganism in new samples
or persistently clinical signs and symptoms or high acute-phase
reactants in the absence of other inflammatory causes) or (iii)
the patient relapsed (same criteria as for persistence but
following a period of clinical improvement).
Statistical analysis
Data were analysed using SPSS software (version 15.0). Simple
linear regressions were conducted to assess changes in the
incidence of vertebral osteomyelitis. To analyse cases of PVO,
either the v2 test or Fisher’s exact test was used to compare
categorical variables, while the t-test or the Mann–Whitney
U-test was used to compare continuous variables. A p value
<0.05 was considered statistically significant.
Results
Incidence study (1991–2011)
The total numbers of episodes of VO and SVO are presented
in Table 1. There were 76 cases of SVO (46 viridans and 30
non-viridans Streptococcus). The prevalence of SVO (1991–
2011) was 14% with respect to the total cases of VO, or 17%
when considering only cases of VO that were microbiologically
confirmed. The proportion of SVO among all cases of VO
during the first (1991–2000) and second decade (2001–2011)
was maintained (14%), whereas the proportion of SVO with
respect to cases of microbiologically confirmed VO increased
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over time (16% and 18%, respectively). During these decades
the proportion of cases of VO-NM significantly increased from
11% to 21% (p 0.01).
Table 2 shows the incidence of cases with respect to
different aetiologies over time. Over the whole period (see
also Fig. 1) there was a progressive and significant increase in
the total number of VO cases per year, as was found for cases
of SVO and of VO-NM. When analysing different species of
SVO there was a progressive increase in the total number of
cases of SVO caused by viridans and non-viridans species but
this was only statistically significant in the latter.
Characteristics of SVO (1991–2011 Malaga and Sevilla, 2003–
2011 Barcelona)
There were 58 cases of SVO (see strains in Table 3).
Differences between cases from different hospitals were only
related to the use of surgical treatment (more common in the
hospitals in Malaga and Seville, p <0.05); therefore, these
described data are not included in further comparisons.
Table 4 shows the main characteristics of patients with
SVO. There were no cases involving rheumatoid arthritis. Back
pain was the most common symptom (95%). The vertebral
segment involved was as follows: lumbo-sacral (32 cases, 55%),
thoracic and thoraco-lumbar junction (15, 26%), cervical (11,
19%); no differences between streptococcal species were
observed in this setting. On admission, the mean values of
C-reactive protein (CRP, mg/L), erythrocyte sedimentation
rate (mm/h), Hb (g/dL) and leucocyte count were 111, 71, 11.6
and 10.8 9 109/L, respectively. The most predominant con-
comitant infection was endocarditis (18 cases), followed by
meningitis (4), arthritis (4), pneumonia (2), skin and soft tissue
infection (2), otitis (1), liver abscess (1) and anal fistula (1).
The mean duration of treatment was 56 days; it was based
on beta-lactams, with the exception of five patients who
received levofloxacin, and one who was given clindamycin.
Surgical treatment was needed in 12 cases (21%): abscess
drainage (10 cases), relief of medullary compression (9) and
spinal stabilization (4). Clinical cure was achieved in all cases
but one, which relapsed but was finally cured with prolonged
treatment. Mean (and median) follow-up was 18 months.
There were nine deaths, none of which was related to PVO.
In order to conduct a more detailed analysis, we compare
the main characteristics of SVO caused by non-viridans and
viridans Streptococcus (Table 4).
Cases of SVO caused by non-viridans streptococcus
(n = 26). Cases of SVO caused by non-viridans streptococcus
tended to be associated with a higher rate of diabetes mellitus,
as well as more fever, neurological symptoms and paraverte-
bral abscess, as compared with those caused by the viridans
group. The presence of concomitant infection was significantly
related to S. pneumoniae (10/13 cases; p <0.05): four arthritis
(three S. pneumoniae and one S. agalactiae), three meningitis
(S. pneumoniae), two pneumonia (S. pneumoniae), two endo-
carditis (one S. pneumoniae and one S. agalactiae), one otitis
(S. pneumoniae) and one skin-soft tissue infection (S. pyogenes).
Cases of SVO caused by viridans streptococcus (n = 32). Cases of
SVO caused by viridans streptococcus showed a significantly
longer diagnostic delay (mean duration of symptoms until
diagnosis), lower values of CRP and higher presence of
endocarditis compared with cases of non-viridans SVO. Con-
comitant infection was: endocarditis (16 cases), meningitis (1),
liver abscess (1), skin-soft tissue infection (1) and anal fistula
TABLE 1. Number of cases of pyogenic vertebral osteomy-
elitis over time
Total (1991–2011) 1991–2000 2001–2011 % Increase
VO (n) 544 189 355 88
VO-M (n) 443 168 275 64
VO-NM (n) 101 21 80 281
SVO (n)a 76 27 49 82
VO, vertebral osteomyelitis; VO-M, microbiologically confirmed VO; VO-NM,
vertebral osteomyelitis with no microbiological diagnosis; SVO, streptococcal
vertebral osteomyelitis; n, number of cases.
aCases of SVO are included in total cases of VO and in cases of VO-M.
TABLE 2. Incidence of pyogenic vertebral osteomyelitis over time
1991–2011 1991–2000 2001–2011
Total cases of VO Increase* Increase* Increase*
+0.066 (0.042–0.090) +0.101 (0.045–0.157) +0.135 (0.075–0.196)
Total cases of SVO Increase* Increase Increase*
+0.009 (0.003–0.015) +0.015 (0.005–0.036) +0.018 (0.002–0.033)
SVO caused by non-viridans species Increase* Increase* Increase
+0.006 (0.001–0.010) +0.019 (0.008–0.031) +0.008 (0.004–0.021)
SVO caused by viridans species Increase Decrease Increase
+0.003 (0.002–0.009)  0.004 (0.024–0.015) +0.009 (0.005–0.024)
Microbiologically confirmed VO Increase* Increase* Increase*
+0.044 (0.023–0.065) +0.085 (0.032–0.138) +0.100 (0.050–0.150)
VO with no microbiological diagnosis Increase* Increase Increase*
+0.022 (0.012–0.032) +0.016 (0.010–0.042) +0.036 (0.001–0.070)
VO, vertebral osteomyelitis; SVO, streptococcal vertebral osteomyelitis.
Incidence data are expressed as the number of episodes per 100 000 inhabitants and year (95% confidence interval).
*p <0.05.
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(1). Microorganisms responsible for endocarditis were as
follows: S. bovis (3), Streptococcus intermedius (3), Streptococcus
viridans sp. (3), Streptococcus mitis (2), Streptococcus mutans (2),
Streptococcus salivarius (2) and group G streptococcus (1). The
subgroup of cases without bacteraemia (n = 9) were caused by
S. viridans sp. (5), S. mitis (1), Streptococcus sanguis (1), Strep-
tococcus anginosus (1) and S. intermedius (1). Characteristics of
and comparisons between the subgroups of viridans SVO with
and without bacteraemia are presented in Table 4.
Comparison between groups of SVO and cases of VO caused
by S. aureus
In comparison with cases of VO caused by S. aureus (n = 50),
SVO caused by non-viridans streptococcus did not differ, except
for the presence of lower rates of bacteraemia; in contrast,
there were significant differences with SVO caused by the
viridans group. (Table 4)
Discussion
This study has sought to describe and analyse a large series of
SVO cases. Our results show an increasing incidence of cases
of SVO during the last two decades, and illustrate that these
cases present several clinical patterns.
An increasing incidence of episodes of VO in the last
decades has been reported [3,4,16] and in this setting a new
epidemiological scenario has been depicted, with a particular
rise in the number of cases of VO-NM or those caused by
fastidious bacteria [3,18,24,25]. The impact of the increasing
incidence of episodes of SVO among all cases of VO is difficult
to establish; while the proportion of these cases of SVO was
maintained during the last two decades, the role of episodes of
SVO in cases of microbiologically confirmed VO increased.
When analyzing these cases of SVO, we showed that the most
remarkable finding was the significant rise in the number of
episodes of SVO caused by non-viridans Streptococcus during
the first decade.
As regards its clinical signs and symptoms, SVO does not
appear to differ from previous large-scale reports of VO
caused by different microorganisms [2,4,26]. However, a
number of particular features are worth noting, especially
the high rate of endocarditis (31%). Moreover, the comparison
of viridans SVO cases with those caused by the non-viridans
group revealed notable differences between the two that merit
further discussion.
Cases involving non-viridans Streptococcus showed a more
acute clinical onset with higher rates of fever and neurological
symptoms. This clinical presentation mimics that of VO caused
by S. aureus [1,2,4]; in fact, only the presence of bacteraemia
and the existence of rheumatoid arthritis were more common
among cases of staphylococcal VO.
Regarding the concomitant infection among SVO cases, the
type and location of infection differed significantly between the
two Streptococcus groups. The association between endocar-
ditis and vertebral osteomyelitis has previously been related to
Gram-positive organisms (Staphylococcus and Streptococcus)
[27–31]. The incidence of endocarditis in large series of VO
has been reported to range from <10% to as high as 30%
[15,30,31]. A study by Mulleman et al. [15] analysed the
relationship between infective endocarditis and streptococcal
and enterococcal vertebral osteomyelitis, and showed that the
incidence of endocarditis was as high as 26%. In line with these
findings, our results also showed a high incidence (31%) in a
TABLE 3. Aetiology of 58 cases of streptococcal vertebral
osteomyelitis
Streptococcus species Cases (n)
Streptococcus agalactiae 13
Streptococcus pneumoniae 11
Streptococcus viridans sp. 11
Streptococcus intermedius 5
Streptococcus bovis 4
Streptococcus sanguis 4
Streptococcus mitis 3
Streptococcus mutans 2
Streptococcus pyogenes 2
Streptococcus anginosus 1
Streptococcus oralis 1
Group G streptococcus 1
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FIG. 1. Incidence of vertebral osteomyelitis (VO) for the period
1991–2011. SVO, streptococcal vertebral osteomyelitis; VO-M,
microbiologically confirmed VO (cases of SVO not included); VO-NM,
VO with no microbiological diagnosis.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O33–O38
O36 Clinical Microbiology and Infection, Volume 20 Number 1, January 2014 CMI
large series of 58 patients with exclusively SVO. Moreover,
our analysis of streptococcal species showed that the viridans
group was responsible for almost all cases of endocarditis
(89%, p <0.05).
Given previous knowledge about differences between
Streptococcus species causing endocarditis [7], echocardiogra-
phy was not routinely performed in all cases of SVO and this
fact may be considered a limitation of our study. Thus,
echocardiography was carried out in 81% of our viridans SVO
cases with bacteraemia but it was only performed in 16% of
non-viridans SVO with bacteraemia. However, it is very
unlikely that this produced an important diagnostic bias, given
the long follow-up of patients. Our comparison of vertebral
osteomyelitis caused by S. aureus with that caused by the
viridans group also showed a significantly higher number of
cases with endocarditis in the latter group, despite the fact that
bacteraemia was even higher in the S. aureus group. Once
again, our results are in agreement with those of Mulleman
et al. [15], who reported endocarditis in only 3% of their
patients with staphylococcal vertebral osteomyelitis. We
believe that the association between endocarditis and verte-
bral osteomyelitis is especially due to the group of viridans
Streptococcus, and thus, it is in this case that performing an
echocardiography should be mandatory.
When considering the presence of concomitant infection
among non-viridans SVOs we noted that S. pneumoniae was a
significant contributor to these cases. Although all these
infections have been previously described in relation to
pneumococcal disease [12,13], we noted that it was not only
respiratory tract infections that were documented in our
patients [8–12].
In the analysis of SVO caused by the viridans group we
showed that patients with bacteraemia often suffered from
endocarditis and their clinical presentation mimicked that for
a sub-acute endocarditis caused by viridans Streptococcus
[7,32]. The clinical scenario of those patients without
bacteraemia was close to that of VO caused by low-virulent
bacteria and VO with no microbiological diagnosis (long
diagnostic delay in older patients who were more likely to
suffer from a debilitating disease with no concomitant
infection) [3,17,18]. These data should be taken into
account when seeking to identify the microorganism respon-
sible for VO, or when initiating an empirical antimicrobial
therapy.
In conclusion, SVO presents a wide range of clinical
patterns. The relationship between VO and the presence of
endocarditis was established with SVO caused by the viridans
group, whereas other concomitant infections were mainly
related to S. pneumoniae. Whereas non-viridans SVO mimics
the characteristics of VO caused by S. aureus, cases of viridans
SVO are significantly more likely to have a sub-acute clinical
presentation. The increased incidence of cases of SVO during
the last decades supports an emerging epidemiological sce-
nario that should be confirmed in further studies.
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TABLE 4. Comparison between groups of vertebral osteomyelitis
Total
SVO (n = 58)
Non-viridans
SVO
(n = 26)
Viridans
SVO
Staphylococcus aureus
VO
(n = 50)
All
(n = 32)
With
bacteraemia
(n = 23)
Without
bacteraemia
(n = 9)
Age (mean years  SD)* 66 ( 13) 63 ( 15) 68 ( 11) 69 ( 10) 66 ( 12) 62 ( 13)
Underlying diseases Diabetes mellitus 13 (22%) 8 (31%) 5 (15%) 2 (9%) 3 (33%) 15 (30%)
Active neoplasm 8 (14%) 4 (15%) 4 (13%) 2 (9%) 2 (22%) 4 (8%)
Immunosuppression 14 (24%) 5 (19%) 9 (28%) 7 (30%) 2 (22%) 10 (10%)
Signs and symptoms Fever† 41 (72%) 20 (77%) 21 (66%) 18 (78%) 3 (33%) 42 (84%)
Neurological symptoms 20 (34%) 11 (43%) 9 (28%) 4 (17%) 5 (55%) 16 (32%)
Paravertebral abscess 36 (62%) 17 (65%) 19 (59%) 13 (56%) 6 (67%) 34 (68%)
Diagnostic delay (mean days  SD)‡,*,† 47 ( 42) 37 ( 39) 55 ( 43) 44 ( 34) 83 ( 52) 30 ( 33)
Concomitant infection*,† 33 (57%) 13 (50%) 20 (63%) 18 (78%) 2 (22%) 19 (38%)
Endocarditis‡,*,† 18 (31%) 2 (8%) 16 (50%) 16 (60%) 0 5 (10%)
Laboratory findings Bacteraemia*,§ 42 (72%) 19 (73%) 23 (72%) 23 (100%) 0 46 (92%)
CRP value (mean  SD)‡,* 111 ( 98) 172 ( 128) 76 ( 47) 79 ( 50) 69 ( 40) 153 ( 96)
VO, vertebral osteomyelitis; SVO, streptococcal vertebral osteomyelitis.
*p <0.05 between viridans SVO (All) and S. aureus VO.
†p <0.05 between viridans SVO with and without bacteraemia.
‡p <0.05 between viridans SVO (All) and non-viridans SVO.
§p <0.05 between non-viridans SVO and S. aureus VO.
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